Is Amwill Health overvalued or undervalued?

As of 18 September 2025, Amwill Health's valuation grade has moved from expensive to fair, indicating a more favorable assessment of its market position. The company is currently fairly valued, with a PE ratio of 11.00, an EV to EBITDA of 9.87, and a ROCE of 16.92%. In comparison to its peers, Sun Pharma has a significantly higher PE ratio of 34.46, while Cipla, which is rated attractive, has a PE ratio of 23.65, highlighting that Amwill Health is positioned more competitively in terms of valuation metrics.
Despite the recent stock performance showing a slight decline of 4.81% over the past month compared to a 2.14% gain in the Sensex, the overall valuation suggests that Amwill Health presents a solid investment opportunity at its current price of 59.00. The company's financial ratios indicate a stable operational performance, making it an appealing choice within the pharmaceuticals and biotechnology sector.